Lupin has received final approval for its Ziprasidone Hydrochloride capsules, 20mg, 40mg, 60mg and 80mg strengths from the United States Food and Drugs Administration (USFDA). Lupin’s Ziprasidone Hydrochloride capsules are AB rated generic equivalent of Pfizer Inc.’s Geodon capsules. Lupin has already commenced shipping the product.
Geodon capsules are a typical antipsychotic and are indicated for Schizophrenia. Pfizer’s Geodon capsules had sales of $1.35 billion as per IMS Health, December 2011. Lupin was one of the first applicant to file an ANDA for Geodon Ziprasidone Hydrochloride capsules, 20mg, 40mg, 60mg and 80mg strengths and is entitled to shared exclusivity.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: